Bayer’s gene therapy CDMO Viralgen cuts ribbon on first phase of $142M viral vector expansion – FiercePharma

Viralgen, the gene therapy CDMO coinedby Bayers Asklepios BioPharmaceutical, is wading into commercial waters.

The Spanish contractor on Wednesday said itcut the ribbon on the first $83 million piece of itsnew factory in the Basque Country, Spain. Viralgen, which specializes in adeno-associated virus (AAV) vectorsthe engineered viruses used to deliver gene therapieshas been helping customers with preclinical through phase 2 projects since 2018.

With the new plant, located in the same San Sebastian technology park as Viralgens existing facility, the company will now be able to tackle projects from pre-clinical stages all the way through commercial medicines, it said.

Thanks to the new plant, Viralgen has expanded its capacity fivefold. The company expects the site will release its first commercial-grade 2,000-liter batches by the middle of next year. Throughout 2021, the company will work to validate its equipment and score certifications.

RELATED:With $71M investment, French CDMO Yposkesi set to double capacity and become a viral vector force

Viralgen has invested more than 70 million($83 million) for the first phase of its manufacturing upgrade. Itplans to drop a total of 120million ($142 million) as it works to buildtwo more buildings there. The company will recruit130 workers to staff thefacility and expects its headcount at the site to surpass 250 by 2022.

Viral vectors are needed for many next-gen drugs, from CAR-T cell therapies and gene therapies to certain COVID-19 vaccinesand thats causing big problems for the industry. The vector shortage is already upon us, and its set to worsen in the coming years unless regulators, biopharmas and contract manufacturers move fast to address shortfalls, GlobalData said in a recent report.

RELATED:CDMO Vibalogics, speeding toward U.S. commercial plant, pumps $50M into viral vector capacity

Answering the call, Viralgen'splant will boastthe distinction of being one of the "largest" AAV factories in the world once it's complete, Viralgen says on its website. The company says it will use the facility to help "democratize" access to gene therapies.

Columbus Venture Partners and Asklepios, also known as AskBio, founded Viralgen in 2017 in a bid to tackle mounting production demands in the gene therapy arena. As of last fall, both Viralgen and AskBio now fly the Bayer banner.

In October, Bayer struck a deal to acquire AskBioand Viralgen by extensionfor $2 billion upfront, plus another $2 billion in milestones. The deal will allow Bayer to tap into AskBios AAV gene therapy platform and a pipeline of clinical-phase treatments for Parkinsons disease, Pompe disease and congestive heart failure.

Read this article:
Bayer's gene therapy CDMO Viralgen cuts ribbon on first phase of $142M viral vector expansion - FiercePharma